Scarica l'app Stockscreener
6.60
0.90%
-0.06
Pre-mercato:
6.99
0.39
+5.91%
Trevi Therapeutics Inc Borsa (TRVI) Ultime notizie
MetLife Investment Management LLC Purchases 19,857 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics Inc (TRVI) Q1 2025 Earnings Call Highlights: Promising Trial Results and ... - Yahoo
Earnings call transcript: Trevi Therapeutics beats Q1 2025 EPS expectations - Investing.com
Trevi Therapeutics (TRVI): Promising Data and Strategic Advances | TRVI Stock News - GuruFocus
Trevi Therapeutics Inc (TRVI) Q1 2025 Earnings: EPS of -$0.09 Beats Estimate, Reports $10.3 Million Net Loss - GuruFocus
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates | TRVI Stock News - GuruFocus
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - Stock Titan
Barclays PLC Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Market Insights: Trevi Therapeutics Inc (TRVI)’s Notable Gain of 1.22, Closing at 6.66 - DWinneX
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of “Buy” from Analysts - Defense World
Trevi Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Invesco Ltd. Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Renaissance Technologies LLC Acquires 29,700 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (TRVI) to Release Quarterly Earnings on Tuesday - Defense World
Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025 - StreetInsider
Trevi Therapeutics to Report First Quarter 2025 Financial Result - GuruFocus
Trevi Therapeutics Inc [TRVI] Records 50-Day SMA of $5.77 - knoxdaily.com
Indo-Asian News Service - Indo-Asian News Service (IANS)
A look at TRVI’s current quarter earnings estimates - uspostnews.com
TRVI’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Quarterly Metrics: Quick and Current Ratios for Trevi Therapeutics Inc (TRVI) - DWinneX
SEC Form DEF 14A filed by Trevi Therapeutics Inc. - Quantisnow
JPMorgan Chase & Co. Boosts Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Recent Insider Activity Suggests Potential Gains for Trevi Therapeutics Inc (TRVI) - knoxdaily.com
What is Trevi Therapeutics Inc (TRVI) Stock Return on Shareholders’ Capital? - Sete News
Press Release Distribution & PR Platform - ACCESS Newswire
Geode Capital Management LLC Has $5.35 Million Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Quarterly Snapshot: Quick and Current Ratios for Trevi Therapeutics Inc (TRVI) - DWinneX
Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI) - The Globe and Mail
Trevi Therapeutics Inc (TRVI)’s results reveal risk - uspostnews.com
Stifel maintains Trevi Therapeutics stock Buy rating, $15 target By Investing.com - Investing.com Canada
12,000 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Acquired by Raymond James Financial Inc. - Defense World
American Century Companies Inc. Buys 24,153 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Rating of “Buy” by Analysts - Defense World
Trevi Therapeutics Sees Unusually Large Options Volume (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Given Buy Rating at Needham & Company LLC - Defense World
Trevi Therapeutics at 24th Annual Needham: Strategic Advances in Cough Treatments - Investing.com Canada
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - Seeking Alpha
Prurigo Nodularis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics - The Globe and Mail
Trevi Therapeutics to Participate in Upcoming April Investor Conferences - The Malaysian Reserve
Trevi's Game-Changing Chronic Cough Treatment Takes Center Stage at 3 Major Healthcare Conferences - Stock Titan
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Sees Significant Growth in Short Interest - Defense World
Charles Schwab Investment Management Inc. Has $713,000 Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
What to expect from TRVI’s earnings report this quarter? - uspostnews.com
Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones - Proactive financial news
Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones | NASDAQ:TRVI - Proactive Investors
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Acquired by Bank of New York Mellon Corp - Defense World
Trevi therapeutics chief scientific officer Sciascia sells $17,364 in stock By Investing.com - Investing.com Australia
Trevi therapeutics chief scientific officer Sciascia sells $17,364 in stock - Investing.com
Trevi therapeutics CEO Jennifer Good sells $34,624 in stock By Investing.com - Investing.com South Africa
Trevi therapeutics CEO Jennifer Good sells $34,624 in stock - Investing.com
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2024 Earnings Call Transcript - Insider Monkey
Q3 EPS Estimate for Trevi Therapeutics Reduced by Analyst - Defense World
Equities Analysts Offer Predictions for TRVI Q2 Earnings - Defense World
Leerink Partnrs Analysts Boost Earnings Estimates for TRVI - Defense World
5.73%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):